Cost-effectiveness of dexamethasone compared with aflibercept in naïve diabetic macular edema
Montes Rodríguez, Paula ; Mateo Gabás, Javier (Universidad de Zaragoza) ; Esteban Floría, Olivia (Universidad de Zaragoza) ; Honrubia Grijalbo, Ana ; Ascaso Puyuelo, Francisco J. (Universidad de Zaragoza)
Resumen: Abstract
Background
To assess the cost-effectiveness of the delayed-release device of dexamethasone compared with aflibercept in the treatment of patients with naïve diabetic macular edema (DME) from a societal perspective in the healthcare sector Zaragoza III in Spain.
Methods
A Markov model with five states defined by visual acuity (VA) in the better-seeing eye (Snellen scale) and an additional death state were constructed. Two cohorts of patients were distributed along the VA states and treated during a year with either dexamethasone or aflibercept. One-year follow-up on each group was performed. Medical costs related to the DME treatment and follow-up, medical costs related to the DME comorbidities, and non-medical-related costs were taken into account. Costs (2020 €), health outcomes (Quality-Adjusted Life Years-QALYs), both discounted at a 3.5% annual rate, and incremental cost-effectiveness ratios (ICER: €/QALY) were determined for a lifetime horizon in the base case analysis.
Results
Patients treated with dexamethasone were €77,349 more costly and provided 2.667 additional QALYs (€29,002/QALY) than those treated with aflibercept. The variable efficiency per patient was calculated dividing the improvement in quality of life (on the VFQ-25 scale) by the cost of the treatment. With the obtained results it can be concluded that the efficiency of treating the patients with dexamethasone is significantly superior than the efficiency of treating them with aflibercept.
Conclusions
The cost per QALY gained with the delayed-release device of dexamethasone compared with the one obtained by aflibercept in the naïve DME population is just below the €30,000 threshold, below which, new drugs are sometimes regarded as cost-effective strategies in Spain. In this model, the key variables with greater impact on the cost-effectiveness results were the selected time horizon, the chosen extrapolation method and the number of aflibercept and dexamethasone injections.
Idioma: Inglés
DOI: 10.1186/s12962-022-00401-z
Año: 2022
Publicado en: Cost Effectiveness and Resource Allocation 20, 1 (2022), 10
ISSN: 1478-7547
Factor impacto JCR: 2.3 (2022)
Categ. JCR: HEALTH POLICY & SERVICES rank: 59 / 87 = 0.678 (2022) - Q3 - T3
Factor impacto CITESCORE: 2.9 - Medicine (Q3)
Factor impacto SCIMAGO: 0.53 - Health Policy (Q2)
Tipo y forma: Artículo (Versión definitiva)
Área (Departamento): Área Oftalmología (Dpto. Cirugía)
Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace.
Exportado de SIDERAL (2024-03-18-14:30:42)
Visitas y descargas
Background
To assess the cost-effectiveness of the delayed-release device of dexamethasone compared with aflibercept in the treatment of patients with naïve diabetic macular edema (DME) from a societal perspective in the healthcare sector Zaragoza III in Spain.
Methods
A Markov model with five states defined by visual acuity (VA) in the better-seeing eye (Snellen scale) and an additional death state were constructed. Two cohorts of patients were distributed along the VA states and treated during a year with either dexamethasone or aflibercept. One-year follow-up on each group was performed. Medical costs related to the DME treatment and follow-up, medical costs related to the DME comorbidities, and non-medical-related costs were taken into account. Costs (2020 €), health outcomes (Quality-Adjusted Life Years-QALYs), both discounted at a 3.5% annual rate, and incremental cost-effectiveness ratios (ICER: €/QALY) were determined for a lifetime horizon in the base case analysis.
Results
Patients treated with dexamethasone were €77,349 more costly and provided 2.667 additional QALYs (€29,002/QALY) than those treated with aflibercept. The variable efficiency per patient was calculated dividing the improvement in quality of life (on the VFQ-25 scale) by the cost of the treatment. With the obtained results it can be concluded that the efficiency of treating the patients with dexamethasone is significantly superior than the efficiency of treating them with aflibercept.
Conclusions
The cost per QALY gained with the delayed-release device of dexamethasone compared with the one obtained by aflibercept in the naïve DME population is just below the €30,000 threshold, below which, new drugs are sometimes regarded as cost-effective strategies in Spain. In this model, the key variables with greater impact on the cost-effectiveness results were the selected time horizon, the chosen extrapolation method and the number of aflibercept and dexamethasone injections.
Idioma: Inglés
DOI: 10.1186/s12962-022-00401-z
Año: 2022
Publicado en: Cost Effectiveness and Resource Allocation 20, 1 (2022), 10
ISSN: 1478-7547
Factor impacto JCR: 2.3 (2022)
Categ. JCR: HEALTH POLICY & SERVICES rank: 59 / 87 = 0.678 (2022) - Q3 - T3
Factor impacto CITESCORE: 2.9 - Medicine (Q3)
Factor impacto SCIMAGO: 0.53 - Health Policy (Q2)
Tipo y forma: Artículo (Versión definitiva)
Área (Departamento): Área Oftalmología (Dpto. Cirugía)
Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace. Exportado de SIDERAL (2024-03-18-14:30:42)
Enlace permanente:
Visitas y descargas
Este artículo se encuentra en las siguientes colecciones:
Artículos > Artículos por área > Oftalmología
Registro creado el 2023-03-30, última modificación el 2024-03-19